These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35144684)

  • 1. Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.
    van der Schaar J; Visser LNC; Bouwman FH; Ket JCF; Scheltens P; Bredenoord AL; van der Flier WM
    Alzheimers Res Ther; 2022 Feb; 14(1):31. PubMed ID: 35144684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sharing Alzheimer's disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data.
    van der Schaar J; Visser LNC; Ket JCF; Groot C; Pijnenburg YAL; Scheltens P; Bredenoord AL; van den Hoven MA; van der Flier WM
    Alzheimers Dement; 2023 Dec; 19(12):5773-5794. PubMed ID: 37496313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The controversy over early diagnosis of Alzheimer's disease: A literature review of the advantages and disadvantages].
    Gräßel E; Lauer N
    Z Evid Fortbild Qual Gesundhwes; 2023 Jun; 179():95-105. PubMed ID: 37263875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease.
    Vanderschaeghe G; Dierickx K; Vandenberghe R
    J Bioeth Inq; 2018 Jun; 15(2):219-230. PubMed ID: 29532386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Speech changes in old age: Methodological considerations for speech-based discrimination of healthy ageing and Alzheimer's disease.
    Ivanova O; Martínez-Nicolás I; Meilán JJG
    Int J Lang Commun Disord; 2024; 59(1):13-37. PubMed ID: 37140204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.
    Forlenza OV; Diniz BS; Teixeira AL; Stella F; Gattaz W
    Braz J Psychiatry; 2013; 35(3):284-94. PubMed ID: 24142092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.
    Rahman-Filipiak A; Bolton C; Grill JD; Rostamzadeh A; Chin N; Heidebrink J; Getz S; Fowler NR; Rosen A; Lingler J; Wijsman E; Clark L;
    Alzheimers Dement; 2023 Sep; 19(9):4270-4275. PubMed ID: 37450489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
    Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P
    Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
    Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.
    Assunção SS; Sperling RA; Ritchie C; Kerwin DR; Aisen PS; Lansdall C; Atri A; Cummings J
    Alzheimers Res Ther; 2022 Apr; 14(1):54. PubMed ID: 35440022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early detection of Alzheimer's disease and dementia prediction in patients with mild cognitive impairment : Summary of current recommendations].
    Rostamzadeh A; Jessen F
    Nervenarzt; 2020 Sep; 91(9):832-842. PubMed ID: 32300816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.